stella
beta
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas — Stella
Recruiting
Back to Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(2 sites)
United States
Houston Methodist Hospital, Houston, Texas
Texas Children's Hospital, Houston, Texas
View full record on ClinicalTrials.gov